Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVE: Panitumumab in Recurrent Ovarian Cancer
NCT01388621Phase 2Unknown
- Sponsor
- Wisp
- Start
- Oct 2011
- Primary completion
- Jul 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in ovarian cancer (2 arms), sponsored by Wisp. Primary endpoint: Progression-Free Survival Rate at 12 months. Status: unknown.
02
Drugs
panitumumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01388621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01388621.